Founded by Cumulus Oncology, which contributes capital and oncology discovery and development expertise to the creation of new biotech companies, Nodus has received seed investment from both Cumulus Oncology and additional investors. Nodus Oncology is a biotech company developing first and best-in-class molecules focused on the DNA damage response (DDR) in patient sub-groups where molecular vulnerabilities exist. Mary-Jane Elliott, Lindsey Neville, Davide Nodus Oncology ”įor more information about Nodus Oncology, please contact: We are excited to expand our portfolio and we look forward to working with LDC to advance this program.”Īdesh Kaul, Chief Financial Officer of Basilea, added: “ We are happy to have found a specialized oncology partner with strong expertise in the DNA damage repair space so that the work on this promising program me can swiftly continue towards the next important milestones. Ian Waddell, Chief Executive Officer of Nodus Oncology, said: “Nodus’ acquisition of Basilea’s PARG inhibitor program demonstrates our ongoing commitment to developing, and bringing to patients, drugs addressing next generation DDR targets. Under the terms of the agreement, Basilea receives an upfront and near-term research milestone payment of CHF 1.0 million and is eligible for further payments, upon the achievement of predefined development, regulatory and sales milestones based on entry to the clinic and regulatory approval in the U.S. The development activities will be transferred from Basilea to Nodus Oncology’s drug discovery partner, the Lead Discovery Center (LDC) to accelerate clinical candidate selection.

PARG is a key enzyme in the repair of DNA damage and essential for tumour cells to grow.

Nodus secures worldwide development and commercialization rights to Basilea’s PARG inhibitor (PARGi) programme – currently at the discovery stage - which has the potential to be a best-in-class treatment for molecularly defined patient sub-groups.

Nodus finance